Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Life Sciences Partners

Founders Clemens Van Blitterswijk Frits Van Der Have Rudy Dekeyser

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 168
Average round size
info
The average size of a deal this fund participated in
$35M
Portfolio companies 102
Rounds per year 6.46
Lead investments 44
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.39
Exits 44
Key employees 11

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Medical Device
Summary

The venture was found in Europe in The Netherlands. The main office of represented VC is situated in the Amsterdam.

The fund was created by Clemens Van Blitterswijk, Rudy Dekeyser. The overall number of key employees were 10.

Opposing the other organizations, this Life Sciences Partners works on 4 percentage points more the average amount of lead investments. The top activity for fund was in 2007. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2014.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Life Sciences Partners, startups are often financed by Kurma Partners, Idinvest Partners, VI Partners AG. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Idinvest Partners, Johnson & Johnson Development Corporation. In the next rounds fund is usually obtained by Novartis Venture Fund, LSP BioVentures, Gimv.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Therapeutics, Biopharma. Among the various public portfolio startups of the fund, we may underline Santarus, Hyperion Therapeutics, Merus Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Life Sciences Partners:
Typical Co-investors
Life Sciences Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Life Sciences Partners:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Tubulis

Biotechnology
Health Care
Life Science
Pharmaceutical
Therapeutics
$151M14 Mar 2024 Munich, Bavaria, Germany

Onera Health

Medical
Medical Device
$35M16 Jan 2024 Palo Alto, California, United States

Vico Therapeutics

Health Care
Medical
Pharmaceutical
$63M05 Jan 2024 Leiden, South Holland, Netherlands

OneProjects

Health Care
Medical Device
$23M18 Dec 2023 Dublin, County Dublin, Ireland

Shinobi Therapeutics

Biotechnology
Therapeutics
$51M12 Dec 2023 -

Nouscom

Biotechnology
Genetics
Health Care
Therapeutics
$79M14 Nov 2023 Basel, Basel-City, Switzerland

VectorY

$152M13 Nov 2023 -

AgomAb Therapeutics

Biotechnology
Health Care
Therapeutics
$111M11 Oct 2023 Ghent, East Flanders, Belgium

AstronauTx

Pharmaceutical
$65M08 Oct 2023 United Kingdom, England, United Kingdom

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Life Sciences Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 168
Average round size 35M
Rounds per year 6.46
Peak activity year 2021
Lead investments 44
Follow on index 0.39
Exits 44
Group Appearance index 0.99

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Tubulis

Biotechnology
Health Care
Life Science
Pharmaceutical
Therapeutics
$151M14 Mar 2024 Munich, Bavaria, Germany

Onera Health

Medical
Medical Device
$35M16 Jan 2024 Palo Alto, California, United States

Vico Therapeutics

Health Care
Medical
Pharmaceutical
$63M05 Jan 2024 Leiden, South Holland, Netherlands

OneProjects

Health Care
Medical Device
$23M18 Dec 2023 Dublin, County Dublin, Ireland

Shinobi Therapeutics

Biotechnology
Therapeutics
$51M12 Dec 2023 -

Nouscom

Biotechnology
Genetics
Health Care
Therapeutics
$79M14 Nov 2023 Basel, Basel-City, Switzerland

VectorY

$152M13 Nov 2023 -

AgomAb Therapeutics

Biotechnology
Health Care
Therapeutics
$111M11 Oct 2023 Ghent, East Flanders, Belgium

AstronauTx

Pharmaceutical
$65M08 Oct 2023 United Kingdom, England, United Kingdom
Crunchbase icon

Content report

The following text will be sent to our editors: